Australia, Nov. 5 -- Intellia Therapeutics Inc., owns the trademark (2578269) for 'HAYQURO' till Aug. 18, 2035.
Status: registered:
Registered/protected
Classes: 5 [Pharmaceutical preparations for the treatment of hereditary angioedema] and 5 [Pharmaceutical and biological preparations; Pharmaceutical and biological preparations for treating and managing hereditary angioedema (HAE) and complications caused by hereditary angioedema (HAE); Pharmaceutical and biological preparations, namely, gene editing preparations for use with protein disorders and genetic diseases; Intravenous injectable gene therapy preparations for treating and managing swelling attacks; Therapeutic agents in the nature of CRISPR/Cas9 protein with guide RNAs targeting the KLKB1 gene to reduce production of plasma prekallikrein and control bradykinin generation]
Type of Mark: Word
Date of Acceptance: Aug. 28
Registration Advertised: Nov. 4
For further details contact Corrs Chambers Westgarth.
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2578269.
Disclaimer: Curated by HT Syndication.
